Screening for impact of popular herbs improving mental abilities on the transcriptional level of brain transporters by PRZEMYSLAW M. MROZIKIEWICZ et al.
223
Acta Pharm. 64 (2014) 223–232 Original research paper
DOI: 10.2478/acph-2014-0020
Screening for impact of popular herbs improving mental











Pharmacogenetics, Department of Clinical
Pharmacy and Biopharmacy, University of
Medical Sciences, 14 Marii Magdaleny
Street, 61-861 Poznan, Poland
2Department of Quality Control of Medicinal
Products and Dietary Supplements, Institute
of Natural Fibres and Medicinal Plants
27 Libelta Street, 61-707 Poznan, Poland
3Department of Pharmacology, University
of Medical Sciences, 5a Rokietnicka Street,
60-806 Poznan, Poland
4Departament of Pharmaceutical Botany and
Plant Biotechnology, University of Medical
Sciences, 14 Marii Magdaleny Street
61-861 Poznan, Poland
5Department of General Pharmacology and
Pharmacoeconomics, Pomeranian Medical
University, Zolnierska 48 Street
70-204 Szczecin, Poland
6Department of Gastroenterology and
Metabolic Diseases, Medical University of
Warsaw, Banacha 1a Street, 02-091 Warsaw,
Poland
Accepted February 27, 2014
There are a number of compounds that can modify the
activity of ABC (ATP-binding cassette) and SLC (solute
carrier) transporters in the blood-brain barrier (BBB). The
aim of this study was to investigate the effect of natural
and synthetic substances on the expression level of genes
encoding transporters present in the BBB (mdr1a, mdr1b,
mrp1, mrp2, oatp1a4, oatp1a5 and oatp1c1). Our results
showed that verapamil caused the greatest reduction in
the mRNA level while other synthetic (piracetam, pheno-
barbital) and natural (codeine, cyclosporine A, quercetin)
substances showed a selective inhibitory effect. Further,
the extract from the roots of Panax ginseng C. A. Meyer ex-
hibited a decrease of transcription against selected trans-
porters whereas the extract from Ginkgo biloba L. leaves
resulted in an increase of the expression level of tested
genes, except for mrp2. Extract from the aerial parts of
Hypericum perforatum L. was the only one to cause an in-
creased mRNA level for mdr1 and oatp1c1. These find-
ings suggest that herbs can play an important role in
overcoming the BBB and multidrug resistance to pharma-
cotherapy of brain cancer and mental disorders, based
on the activity of selected drug-metabolizing enzymes
and transporters located in the BBB.
Keywords: ABC proteins, P-glycoprotein, blood-brain bar-
rier, expression level, herbal substances
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Treatment of several diseases, especially brain diseases and neurological disorders,
remains unexplained and creates many therapeutical problems (1). The major challenge
for drug delivery to the brain parenchyma is the presence of the blood-brain barrier (BBB),
which limits the access of drugs into this place (2). The BBB is a complex of physiologi-
cal mechanisms, involving physical and biochemical barriers, which prevent penetration
of the many endogenous and exogenous substances that may be toxic to the central ner-
vous system (CNS) from the blood into the brain (1, 3). The blood-brain barrier involves
transmembrane transporters that transport substrates of brain cells to the vascular lumen
vessels allowing selective transport of larger molecules as well as those actively export-
ing feedstock to blood vessels, leading to reduction of intracellular concentration (4, 5).
Active transporters involved in the functioning of the blood-brain barrier and the
phenomenon of multidrug resistance (MDR) include P-glycoprotein (P-gp), solute car-
rier (SLC) family transporters such as OATP1A4, OATP1A5, OATP1C1 and multidrug
resistance-associated proteins (MRP), inter alia, Mrp1 and Mrp2. P-gp belongs to the fa-
mily of proteins characterized by the presence of a highly conserved motif, called the
ATP-binding cassette (ABC) (6). SLC transporters including OATP1A4 (SLCO1A4),
OATP1A5 (SLCO1A5) and OATP1C1 (SLCO1C1) are expressed in the brain and play an
important role in the organic anion transport. The effectiveness of synthetic drugs and
different plant bio-active metabolites that affect these transporters is inhibited due to
their limited ability to penetrate and rapid process of removing substances from the bra-
in (7, 8). The occurrence of such interactions is confirmed by animal models and clinical
trials in intestinal epithelial cells for P-glycoprotein (9).
In addition, there are few studies on the effects of inhibitors of herbal origin on the
level of expression of transporter gene conditioning, phenomenon of multidrug resist-
ance and the blood brain barrier (10). These studies mainly address the impact of syn-
thetic drugs and herbal substances on the P-gp expression level. Results suggest that cer-
tain synthetic substances at higher doses, such as as verapamil, are inhibitors for P-gp.
However, their highly adverse side effects such as verapamil’s cardiac toxicity prevent
their practical application in overcoming the multidrug resistance and the blood-brain
barrier (10, 11). Therefore, the search for safe P-glycoprotein inhibitors of herbal origin is
a promising way, in view of fewer side effects, towards normal tissues in comparison
with synthetic drugs.
It has been proven that, depending on their concentration, certain flavonoid com-
pounds (kaempferol, daidzein, quercetin, genistein) inhibit the activity of the P-gp pump
by reducing the resistance of selected cell lines to vinblastin (12). Moreover, curcumin
(from rhizomes of Curcuma longa, L., Zingiberaceae Lindl.), ginsenosides (from roots of
Panax ginseng C.A. Meyer, Araliaceae Juss.), piperine (from fruits of Piper nigrum L., Pipe-
raceae, C. Agardh), tannins (from leaves of Camellia sinensis L. Kuntze, Theaceae D. Don)
and silymarin (from fruits of Silybum marianum L. Gaertner, Asteraceae Dum.) may inhibit
the activity of P-gp. Bergamotin and quercetin from grapefruit juice also modulate the
activity of P-gp (13, 14).
Taking into account the growing interest among consumers and patients in prepa-
rations of plant origin commonly used in the treatment and prevention of symptomatic
neurological disorders, there is a need to clarify their potential impact on the CNS-
-disorder pharmacotherapy. According to our knowledge, relatively little information is
available on the effects of plant extracts on the BBB and gene expression in the brain. In
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the case of MRP1 and MRP2, only a few analyses have been performed and are mainly
associated with expression in the liver where the drug is primarily metabolized (8, 13).
Therefore, the aim of this study was to demonstrate the effect of the selected synthetic
drugs as well as substances of plant origin that may play an important role in blocking
the transporter functioning in the blood-brain barrier, such as P-glycoprotein (MDR1),
proteins associated with multidrug resistance (MRP1, MRP2), SLC transporters OATP1A4
(SLCO1A4) OATP1A5 (SLCO1A5) and OATP1C1 (SLCO1C1) in an in vivo rat model.
EXPERIMENTAL
Chemicals
Verapamil, as a standard chemical compound having inhibitory properties against the
relevant transporters, and piracetam were purchased from Sigma-Aldrich Chemical Com-
pany (USA). Phenobarbital was purchased from PGF Cefarm-Poznan Sp. z o.o. (Poland).
Natural substances
Quercetin [quercetin dihydrate (purity = 98 % (HPLC)], codeine (codeine-d3 solu-
tion 1 mg mL–1 in methanol, 99 %) and cyclosporine A (purity = 98.5 %) A were pur-
chased from Sigma-Aldrich Chemical Company.
Standardized herbal extracts
Standardized extracts such as that of aerial parts Hypericum perforatum L. (Hyperic-
aceae, Juss.), roots of Panax ginseng C. A. Meyer (Araliaceae Juss.), leaves of Ginkgo biloba
L. (Ginkgoaceae Engl.) were used. These were obtained from Finzelberg GmbH & Co. KG,
Germany). The content of active compounds of selected dry alcoholic extracts was de-
termined using high performance liquid chromatography (HPLC) methods according to
the procedures included in European Pharmacopoeia (15). Analysis of dried ethanolic ex-
tracts from dried aerial parts of Hypericum perforatum (ethanol 60 %, V/V) revealed the
presence of hypericin (0.3 %) and hyperforin (0.61 %) (13), from a dried root of – Panax
ginseng (ethanol 60 %, V/V) the presence of ginsenosides (27.1 %) (14), from leaves of
Ginkgo biloba (ethanol 80 %, V/V) the presence of flavonol glycosides (24.5 %), terpene
lactones (13 %) and ginkgolic acids (5.0 ?g g–1) (15).
Animals and treatment
The experiment with male Wistar rats (300–450) was performed in accordance with
Polish govermental regulations and in agreement with the Local Ethics Committee on
the Use of Laboratory Animals in Poznan. Male Wistar rats were housed in plastic cages
at the Department of Pharmacology, Poznan University of Medical Sciences. Animals
were kept in a climate-controlled room under a 12-h light/dark cycle and had access to a
commercial rat chow and tap water ad libitum. They were acclimatized for a few days
prior to the experiment. All rats were randomly divided into 9 groups from A to J (8 per
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group), which received standardized herbal extracts, natural and synthetic substances
suspended in distilled water for 21 days. Group A was treated with verapamil as a po-
tent inhibitor of transporters (20 mg kg–1 day–1, p. o.) whereas group B received cyclo-
sporin A (5 mg kg–1 day–1, p. o.) having also inhibitory properties against the relevant
transporters. The next two groups (C and D) were treated with synthetic substances such
as piracetam (200 mg kg–1 day–1, p. o.) and phenobarbital (80 mg kg–1 day–1, p. o.). Group
E was treated with quercetin (500 mg kg–1 day–1, p. o.) while group F received codeine
(20 mg kg–1 day–1, p. o.). Another group (group G) was given the standardized extract
from aerial parts of Hypericum perforatum (300 mg kg–1 day–1, p. o.) whereas group H
was treated with the root extract of Panax ginseng (30 mg kg–1 day–1, p. o.). Group I was
given the leaf extract of Ginkgo biloba (200 mg kg–1 day–1, p. o.) and group J was used as
a control and was only fed standard diet. Two hours after the last administration, rats
were decapitated. The brain tissue (hippocampus) was immediately frozen in liquid ni-
trogen and stored at –80 °C.
RNA extraction and cDNA synthesis
Total cellular RNA was isolated from the rat hippocampus using TriPure Isolation
Reagent (Roche, Germany) according to the manufacturer’s protocol. Concentrations
and the purity of RNA were determined by measuring the absorbance at 260 and 280 nm
using a spectrophotometer (BioPhotometer Eppendorf, USA). RNA samples were stored
at –80 °C. Complementary DNA was synthesized from 1 µg of total RNA in a total volume
of 20 µL using the Transcriptor cDNA First Strand Synthesis Kit (Roche) and oligo(dT)18
primer (Roche) according to the manufacturer’s protocol. The obtained transcripts were
stored at –20 °C or used directly for the real-time quantitative reverse transcription poly-
merase chain reaction (RT-PCR).
Determination of mRNA levels by quantitative real-time
Real-time PCR (RT-PCR) was carried out using a LightCycler® 480 instrument (Roche)
and a LightCycler®480 SYBR Green I Master (Roche) according to the manufacturer’s
protocol. Amplicon size and reaction specificity were confirmed by agarose gel electro-
phoresis and melting curve analysis. The sequences of the primers for mdr1b, oatp1a4,
oatp1a5 and oatp1c1 were designed using the Oligo 6.0 program (National Biosciences,
USA). Primers for mrp1 and mrp2 were used according to Sugamo et al. (16) and the
primers for mdr1a were designed by Andersson et al. (17). All oligonucleotide sequences
were synthesized by TIB Molbiol (Poland) and are summarized in Table I. GAPDH cDNA
amplification product was used as a housekeeping gene (endogenous internal standard)
for normalization. Thermal cycling conditions for analyzed genes were the following: for
GAPDH, 35 cycles of 95 °C for 20 s, 59 °C for 15 s, 72 °C for 15 s; genes encoding trans-
membrane transporters, 40 cycles of 95 °C for 20 s, 59 °C for 15 s, 72 °C for 15 s. RT-PCR
reaction was carried out in a 10 ìL reaction mixture. Each PCR set was monitored by
measuring the increase in fluorescence by the binding of SYBR Green I dye to the gener-
ated double-stranded cDNA. Standard curves were prepared from the dilution of cDNA
and generated from a minimum of four data points. All quantitative PCR reactions were
repeated twice. The data were evaluated using the LightCycler® 480 Basic Software
(Roche Applied Science, Berlin, Germany).
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Statistical analysis
The mRNA content of the studied genes was expressed as mean ± SEM. Experimen-
tal data were analyzed using the SPSS 17.0 for Windows software. Mean values were
compared by means of the one-way ANOVA test. The value of p<0.05 was considered as
statistically significant.
RESULTS AND DISCUSSION
In this study, we analyzed the influence of synthetic and natural substances as well
as herbal extracts on the expression level of genes encoding transporters involved in
BDB and MDR. Our results showed that administration of verapamil as a potential inhi-
bitor of xenobiotic transporters caused a significant decrease of the expression level in
all the examined genes [mdrla (93 %), mdrlb (85 %), mrpl (83 %), mrp2 (99.5 %), oatpla4
(75 %), oatpla5 (90 %), oatplcl (67 %)] compared to the control group (Figs. 1 and 2).
Cyclosporin A inhibited the expression level by 67 % (p < 0.0001) for Mdr1a, 47 % (p <
0.0001) for Mrp1, 75 % (p < 0.001) for Mrp2 and not significantly for oatp1a4 (22 %). Ad-
ministration of codeine and piracetam also resulted in a decrease of the mRNA level in
all the examined genes for transporters except for oatp1c1, whereas phenobarbital caus-
ed an increase of expression level in all the examined genes except for mrp2 where de-
crease of 99.5 % was envidenced (p<0.0001). Significant induction was observed for
mdr1a (6.56-fold, p<0.0001) and mdr1b (7.4-fold, p<0.0001).
In the case of herbal extracts, we showed that Panax ginseng resulted in a decrease of
the mRNA level in the examined genes [mdr1a (23 %), mrp1 (63 %), mrp2 (24 %), oatp1a4
(32 %), oatp1a5 (33 %), oatp1c1 (21 %)] except for mdr1b. The average mdr1b mRNA
expression was higher by 140 % (p<0.05) in the study group compared to the control
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Table I. Sequences of primers used for the RT-PCR analysis
Gene
Primer sequence
Forward (5’ ? 3’)
Primer sequence




Mdr1a GGC CAC ATG ATC AAG ACG AAC AAG TTG CTG TTC TGC C 243
Mdr1b TGA CGT GAA TGA CGC TGG CAC ATG GCA GAT GAC AAC C 207
Mrp1 ATG CTC AAG TGG ACA TGT TTC G TCG ATT CTG GAC ATG GAT TCG 144
Mrp2 CAG GCA ATG GTG TGT ACG AA A
AGG AGT GCT CGT ATC AGA GTC
TGA
105
Oatp1a5 CCA CAT CTA TAG TTG GAT TCA TGA GGA CAA GTT GCT TGT AG 221
Oatp2 TCG GTA TCC CCA CAT CTA TAG GAG GAC ACG TTG CTT GTA GG 226
Oatp1c1 GAG CAG GAT GCC TGG TCA T ACT GGT ATC CAC TTC ACA CT 221
Oatp1a4 TCG GTA TCC CCA CAT CTA TAG GAG GAC ACG TTG CTT GTA GG 226
GAPDH GAT GGT GAA GGT CGG TGT G ATG AAG GGG TCG TTG ATG G 108
GAPDH – glyceraldehyde-3-phosphate dehydrogenase
(Fig. 3). Similar conclusions concerning P-gp were made in the in vivo study conducted
by Zhang et al. (18). These authors showed that long-term effects of Panax ginseng caused
induction of intestinal and brain endothelium P-glycoprotein expression in rats (18).
Another interesting study by Zhang et al. (19) demonstrated that 20(S)-ginsenoside Rh2
from Panax ginseng noncompetitively inhibited P-gp in vitro and in vivo as an example of
herb-drug interaction. The in vitro study using rat primary hepatocytes revealed an in-
crease of the mrp2 mRNA level by the addition of red ginseng (100 and 500 µg mL–1)
(20). However, this observation concerned the expression in the liver and not in the brain.
Despite the few data on the impact of Panax ginseng on the mRNA level of transporters,
our results suggest that the tested extract may have an effective use in overcoming the
BBB or MDR by reducing adverse events in comparison with synthetic drugs. However,
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Fig. 1. Effect of synthetic and natural substances on the expression level of genes encoding trans-
membrane transporters (mdr1a, mdr1b, mrp1 and mrp2) in the rat hippocampus after 21 days of
administration. Control groups are defined as 100 %. Data are presented as mean ± SEM (n = 8).
Asterisks indicate significance (one-way ANOVA test): * p < 0.05, ** p < 0.001, *** p < 0.0001.
Fig. 2. Effect of synthetic and natural substances on the expression level of genes encoding SLC
transporters (oatp1a4, oatp1a5 and oatp1c1) in the rat hippocampus after 21 days of administration.
Control groups are defined as 100 %. Data are presented as mean ± SEM (n = 8). Asterisks indicate
significance (one-way ANOVA test): * p < 0.05, *** p < 0.0001.
further studies are needed concerning the influence of Panax ginseng on the transcription
of transporter genes, taking into account the duration of extract administration, its dose
and composition.
Further, we also analyzed the influence of Hypericum perforatum on the mRNA level
in rat hippocampus. Our results showed a noticeable increase of the expression level in
the brain tissue by 275 % (p<0.001) for mdr1b and 41 % (p<0.05) for oatp1c1. A signi-
ficant mRNA reduction by 68.5 % was observed for mrp1 (p<0.05) (Fig. 3). In the study
by Hennessy et al. the authors showed thatt he Hypericum perforatum extract (0.15 %,
1800 mg in 16 days) may cause an increase of the expression level of the MDR1 gene in
the cells of the peripheral blood lymphocytes (PBMCs) even up to 4.2-fold (21). Modu-
lating effect of active compounds of the Hypericum perforatum extract (LI160) on P-gp
also confirmed the results of the in vitro study carried out in two cell lines: porcine brain
capillary endothelial cells (PBCEC) and VLB-100 (human lymphocytic leukemia cell line)
(22). Another interesting study, conducted by Garrovo et al. (23) showed a significant
increase in the transcripts for mdr1a and mdr1b in all the organs examined (brain, liver,
kidney and heart). The increase of mRNA level for mrp2 in the rats treated with St.
Johns’s wort (100 and 1000 mg kg–1) was only observed in the liver and kidney.
In addition, we showed the inductive effect of the standardized Ginkgo biloba extract
on the mRNA level of mdr1 (9.1-fold, p<0.001), oatp1a4 (1.25-fold, p<0.0001), oatp1a5
(13.3-fold, p<0.0001) and oatp1c1 (4.5-fold, p<0.0001), whereas a decrease of transcrip-
tion was noted only for mrp2 by 81 % (p<0.001) (Fig. 3). In the study conducted by Li et
al. (24), the authors analyzing active substances of Ginkgo biloba showed induction of
CYP2B6, CYP3A4, UGT1A1, MDR1, and MRP2 by EGb 761, ginkgolide A (GA) and gink-
golide B (GB), but not by bilobalide (BB) or the flavonoids (quercetin, kaempferol) in hu-
man primary hepatocytes. These results suggest that the substances isolated from Ginkgo
biloba may act differently in comparison with the whole extract. We believe that the use
of Ginkgo biloba extract in the treatment of CNS diseases would be effective only in the
case of drugs that are substrates for MRP2. However, these studies need to be confirmed
in clinical trials of the effectiveness of Ginkgo biloba in reducing MRP2 gene expression.
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Fig. 3. Influence of standardized herbal extracts on the expression level of genes encoding trans-
membrane transporters in the rat hippocampus after 21 days of administration. Control groups are
defined as 100 %. Data are presented as mean ± SEM of 8 rats in each group. Asterisks indicate sig-
nificance (one-way ANOVA test): * p < 0.05, ** p < 0.001, *** p < 0.0001.
In this study we also analyzed the influence of quercetin on the transcriptional level
of tested transporters. The inductive effect of quercetin was observed for mdr1b by 50 %
(p<0.0001), oatp1a4 by 18 % (p<0.0001) and oatp1c1 by 293 % (p<0.0001). However, a sig-
nificant decrease of expression by 99.8 % (p<0.0001) was noted for mrp2 (Figs. 1 and 2).
Similar results were obtained by Scambia et al. (25) as well as Shapiro and Ling (26), who
showed that quercetin inhibited P-gp. Moreover, it is suggested that low concentrations
of quercetin stimulate P-gp. However, high concentrations of this compound inhibit P-gp
activity. Explanation of these controversial observations is unknown. In addition, despi-
te similar molecular structures and substrate spectra of MRP1 and MRP2, it was shown
that MRP1 has different structural requirements for its inhibition compared to MRP2.
Fewer compounds have been shown to be potent inhibitors of MRP2. For example, fla-
vonoids such as apigenin, kaempferol and quercetin may inhibit MRP1 but not MRP2-
-mediated transport (27). Furthermore, potential in vivo drug interactions due to herbal
substances’ inhibition of MRP1 and MRP2 is still unclear, because the mechanism of in-
teraction between xenobiotic transporters and substances of plant origin may involve the
binding to the nucleotide binding domains and/or the substrate binding site (27). Thus,
further studies are needed in order to correctly interpret the animal data and to evaluate
the clinical potential for herb-drug interactions.
CONCLUSIONS
Both the substances of herbal origin and synthetic drugs can modulate the expres-
sion of transporters in the blood-brain barrier. Verapamil caused the greatest reduction
of the mRNA level of each of the analyzed genes while other synthetic substances show-
ed a selective inhibitory effect. In the case of herbal extracts, it was shown that Panax
ginseng can decrease the transcription against selected transporters whereas Ginkgo bil-
oba increases the expression level of genes, except for mrp2. Hypericum perforatum only
caused an increase of mRNA transcription for mdr1 and oatp1c1. These findings suggest
that herbal substances having inhibitory activity against transporters can play an im-
portant role in overcoming the BBB and MDR leading to improved brain drug delivery
and reduced CNS pathology. In conclusion, the results obtained by our team clearly in-
dicate the validity of the search for potential modulators of the BBB in order to ensure an
effective and safe pharmacotherapy of CNS disorders.
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Acronyms. – ABC – ATP-binding cassette transporters, BBB – blood-brain barrier, CYP – cyto-
chrome P450, CNS – central nervous system, GAPDH – glyceraldehyde 3-phosphate dehydroge-
nase, MDR – multidrug resistance, MDR1 – multidrug resistance protein 1, MRP1 – multidrug resis-
tance-associated protein 1, MRP2 – multidrug resistance-associated protein 2, OATP – organic anion
transporting polypeptide, P-gp – P-glycoprotein, SLC – solute carrier transporters, UGT – UDP-glu-
curonosyltransferase.
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